Minoxidil

證據等級: L5

預測適應症: 10 個

Minoxidil: From Androgenetic Alopecia to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Minoxidil is a potassium channel opener approved in many countries for androgenetic alopecia (pattern hair loss) and, at higher doses, for severe refractory hypertension. The TxGNN model predicts it may be effective for Hypotrichosis Simplex of the Scalp, a rare hereditary hair loss disorder for which no established treatment currently exists, with 0 clinical trials and 3 publications (case series and case reports) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Androgenetic alopecia; severe hypertension (FDA/EMA approved in other markets; not registered in Denmark)
Predicted New Indication	Hypotrichosis Simplex of the Scalp
TxGNN Prediction Score	~99.9999%
Evidence Level	L3
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism of action data could not be retrieved from DrugBank for this evidence pack; however, published literature within the pack provides a detailed picture. Minoxidil is a prodrug metabolised in the hair follicle by sulfotransferase (SULT1A1) into minoxidil sulfate, its active form. This active metabolite opens ATP-sensitive potassium (K_ATP) channels in vascular smooth muscle and dermal papilla cells, causing vasodilation and prolongation of the anagen (active growth) phase of the hair cycle. Additionally, minoxidil activates the Wnt/β-catenin signalling pathway, exerts anti-inflammatory effects, and has mild antiandrogenic properties — collectively creating a multi-pathway stimulus for hair follicle survival and growth (PMID 34159872).

Hypotrichosis simplex of the scalp (HSS) is a rare autosomal dominant monogenic disorder caused by mutations in CDSN, encoding the desmosomal protein corneodesmosin, which is essential for hair follicle structural integrity. The disease presents in childhood as progressive diffuse thinning, primarily reflecting impaired follicular cycling rather than complete follicular destruction. Because residual functional follicles remain present, minoxidil’s anagen-prolonging and dermal papilla-stimulating properties are mechanistically well positioned to address the underlying follicular dysfunction — a direct correspondence that the repurposing rationale from the evidence pack explicitly highlights.

This mechanistic alignment is further validated by direct clinical reports: PMID 35761391 explicitly employs oral minoxidil combined with growth factors to treat hereditary hypotrichosis simplex, and PMID 36651821 reports successful improvement with topical minoxidil 2% combined with platelet-rich plasma in a confirmed HSS patient. Both androgenetic alopecia (minoxidil’s established indication) and HSS involve impaired follicular cycling and reduced hair density, making the mechanistic bridge between them strong and biologically coherent.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35761391	2022	Case Series	Dermatologic Therapy	Oral minoxidil combined with growth factors used to treat hereditary hypotrichosis simplex of the scalp; reports clinical hair density improvement
36651821	2023	Case Report	J Dermatological Treatment	14-year-old with hereditary HSS treated with combined platelet-rich plasma injections and topical minoxidil 2%; reports successful outcome in a condition otherwise lacking satisfactory treatment
39902296	2024	Case Report	Frontiers in Genetics	Familial HSS (CDSN mutation confirmed) in an 8-year-old male treated with botanical extract and minoxidil combination; highlights that definitive effective treatments remain lacking for this condition

Denmark Market Information

Minoxidil does not hold a marketing authorisation in Denmark. There are no active licenses in the Laegemiddelstyrelsen national registry, and no centralised EMA authorisation covers the Danish market for this drug. Minoxidil is, however, widely authorised across other EU member states and in the United States (FDA OTC approval for 2% and 5% topical solution, 5% foam) for androgenetic alopecia.

Any clinical use in Denmark would require either a named-patient/compassionate use application or a formal marketing authorisation application.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No drug-drug interaction data were retrieved in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis is compelling and the unmet medical need is high — HSS has no approved pharmacological treatment — but the current evidence rests entirely on three case-level reports (evidence level L3) with no registered clinical trials, which is insufficient to support a formal repurposing programme or a regulatory application at this stage.

To proceed, the following is needed:

Retrieval of formal mechanism of action and safety data from DrugBank (currently a data gap)
Full review of the Laegemiddelstyrelsen / EMA SmPC equivalents for approved minoxidil products in other EU markets, including warnings, contraindications, and paediatric safety data
Establishment of a prospective registry or pilot study systematically documenting outcomes in HSS patients treated with oral or topical minoxidil, with genetic confirmation of CDSN mutation status
Consultation with Laegemiddelstyrelsen on orphan drug designation potential — HSS qualifies as a rare disease, and this designation could accelerate and incentivise the development pathway
Assessment of the optimal route of administration (topical vs. low-dose oral) and dosing for a paediatric-onset rare disease population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.